BridgeBio公布Encaleret在常染色体显性低钙血症1型患者中积极的三期顶线结果

投资观察
Oct 29, 2025

10月29日 - BridgeBio Pharma, Inc.公告称:*BRIDGEBIO公布Encaleret在常染色体显性低钙血症1型患者中的积极三期顶线结果*BRIDGEBIO PHARMA INC:CALIBRATE研究显示Encaleret在ADH1患者中满足所有预设的主要和关键次要疗效终点*BRIDGEBIO PHARMA INC:计划于2026年启动Encaleret在慢性甲状旁腺功能减退症和儿科ADH1中的注册研究*BRIDGEBIO PHARMA INC:Encaleret耐受良好,研究药物未出现相关停药情况*BRIDGEBIO PHARMA INC - 76%的Encaleret参与者达到了目标钙水平*BRIDGEBIO PHARMA INC - 91%的Encaleret参与者的PTH水平超过参考范围*BRIDGEBIO PHARMA INC - 计划在2026年上半年提交新药申请

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10